Clinical response (SLEDAI) to treatment at weeks 12 and 24: interim analysis in the target population
| Lupuzor | |||
|---|---|---|---|
| Group 1 (200 μg every 4 weeks) | Group 2 (200 μg every 2 weeks) | Group 3 (placebo) | |
| Week 12 | n=34 | n=39 | n=41 |
| Responders, n (%) | 23 (67.6) | 20 (51.3) | 17 (41.5) |
| p<0.025 | p=0.19 | – | |
| Week 24 | n=19 | n=21 | n=24 |
| Responders, n (%) | 16 (84.2) | 14 (66.7) | 11 (45.8) |
| p<0.025 | p=0.15 | – | |
p Values compare Lupuzor with placebo. Drop-outs are considered as non-responders. All data available at the cut-off date are presented.
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.